Abstract: An output-decision-based negative feedback control method and system. The method includes: receiving, by an output decider, output responses of at least two heterogeneous functional equivalents, and dividing numbers corresponding to the at least two heterogeneous functional equivalents into at least one set according to the output responses; determining, by the output decider, credibility of each set according to the output responses, and sending the at least one set and the credibility corresponding to each set to a feedback controller via decision information; generating, by the feedback controller, a first scheduling policy and/or a second scheduling policy according to the decision information; and sending, by the feedback controller, the first scheduling policy to an input proxy, and/or sending a change instruction to the heterogeneous functional equivalent indicated by the second scheduling policy. The method can prevent in advance and process a heterogeneous functional equivalent that may be faulty.

Abstract: The present disclosure provides a semiconductor device and a fabrication method thereof. The semiconductor device includes a substrate, a first nitride semiconductor layer, a second nitride semiconductor layer, and a carbonitride semiconductor layer. The first nitride semiconductor layer is over the substrate. The second nitride semiconductor layer is formed on the first nitride semiconductor layer and has a greater bandgap than that of the first nitride semiconductor layer. The carbonitride semiconductor layer is between the substrate and the first nitride semiconductor layer.

Abstract: The present invention provides a semiconductor device, comprising: a substrate (10); a stack of III-nitride transition layers (11) disposed on the substrate (10), the stack of III-nitride transition layers (11) maintaining an epitaxial relationship to the substrate (10); a first III-nitride layer (121) disposed on the stack of III-nitride transition layers (11); and a second III-nitride layer (122) disposed on the first III-nitride layer (121), the second III-nitride layer (122) having a band gap energy greater than that of the first III-nitride layer (121), wherein the stack of III-nitride transition layers (11) comprises a first transition layer (111), a second transition layer (112) on the first transition layer (111), and a third transition layer (113) on the second transition layer (112), and wherein the second transition layer (112) has a minimum aluminium molar ratio among the first transition layer (111), the second transition layer (112) and third transition layer (113).

Abstract: Semiconductor device structures and methods for manufacturing the same are provided. The semiconductor device structure includes a substrate, a semiconductor layer on the substrate, and a patterned dielectric layer disposed on the substrate and covered by the semiconductor layer. The patterned dielectric layer is configured to prevent a constituent in the semiconductor layer from diffusing into the substrate. The semiconductor device structure further includes a first nitride semiconductor layer on the semiconductor layer and a second nitride semiconductor layer on the first nitride semiconductor layer. A band gap of the second nitride semiconductor layer is greater than a band gap of the first nitride semiconductor layer.

Abstract: Semiconductor device structures and methods for manufacturing the same are provided. The semiconductor device structure includes a substrate, a first layer and a second layer. The first layer is disposed on and in contact with the substrate. The first layer includes AlX1Ga(1-X1)N, wherein 0.5?X1<1. The second layer is disposed on and in contact with the first layer. The second layer includes Al, Ga and N.

Abstract: A surgical instrument includes a housing, a shaft coupled to and extending distally from the housing, an end effector assembly disposed at a distal end of the shaft, a movable handle coupled to the housing, a drive assembly coupled to the end effector assembly, and an extension mechanism disposed within the housing. The extension mechanism is configured to couple to the shaft and between the movable handle and the drive assembly for moving the shaft and drive assembly between a retracted position and an extended position relative to the housing. The extension mechanism is coupled between the movable handle and the drive assembly in each of the retracted and extended positions such that the movable handle is operable to effect manipulation of the end effector assembly in each of the retracted and extended positions.

Abstract: A sheath stabilizer can include a housing, a clamp in the housing, and an adhesive pad disposed on a base of the housing. The housing can include a sheath passageway longitudinally extending through the housing and the base oblique to the sheath passageway. The clamp can be located in a proximal-end portion of the housing around the sheath passageway. The adhesive pad can be disposed on the base and can be configured for adhering the sheath stabilizer to at least a patients skin. The sheath stabilizer can be part of a sheath-and-stabilizer assembly, which can include a sheath configured for percutaneous access. Methods for the sheath stabilizer are described.

Abstract: Disclosed is an articulated stiffening cannula (100, 200, 300, 400). The articulated stiffening cannula (100, 200, 300, 400) include a cannula tube (110, 210, 310, 410), a compound hub (130, 230, 330, 430) disposed about a proximal-end portion of the cannula tube (110, 210, 310, 410) and an articulation mechanism controlled by a rotatable element (132, 232, 332) of the compound hub (130, 230, 330, 430). The cannula tube (110, 210, 310, 410) can include a flexible hinge (114, 214, 314, 414) along a distal length of the cannula tube (110, 210, 310, 410), and can be configured to articulate at the flexible hinge (114, 214, 314, 414) for adjusting a cannula-tube angle between a distal-end portion of the cannula tube (110, 210, 310, 410) and a proximal length of the cannula tube (110, 210, 310, 410).

Abstract: A dynamic dispatching method for semiconductor manufacturing system relates to a dynamic dispatching rule based on self-organization for dispatching in a semiconductor manufacturing system, including S1: setting roles and parameters of self-organization units, and defining key nodes in a production environment; S2: constructing a negotiation mechanism between the self-organization units, and designing a decision-making and dispatching subject ESOU; S3: according to a decision instruction of the ESOU, designing a LSOU allocation dispatching unit for distinguishing single-batch processing and multi-batch processing; and S4: designing a dispatching mechanism based on the self-organization units to implement dynamic semiconductor dispatching. The dynamic dispatching method includes three aspects: role definitions of self-organization units, a negotiation mechanism between the self-organization units and a decision-making method thereof.

Abstract: A needle-tract assistants (100, 200) for establishing a needle tract of a predetermined length, including a needle thruster (110, 210) and a needle-in-catheter assembly (130, 230) removably loaded in the needle thruster (110, 210). The needle thruster (110, 210) can include a cradle (112, 212), a carriage(114, 214) within the cradle (112, 212), and a plunger (116, 216) coupled to the carriages (114, 214). The carriages (114, 214) can be configured to move between a proximal-end portion and a distal-end portion of the cradle(112, 212). The plungers (116, 216) can be configured to move the carriages (114, 214) within the cradle(112, 212). The plungers (116, 216) can also be configured to allow a user to set the predetermined length of the needle tract before establishing the needle tract.

Abstract: The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I). Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and/or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.

Abstract: A method for making a catalyst for ozone decomposition includes: adding a reducing agent into a water solution of a permanganate salt to obtain a first reaction liquid, and heating the first reaction liquid under continuous stirring to form a birnessite-type manganese dioxide; and adding the birnessite-type manganese dioxide into a water solution of an ammonium salt to obtain a second reaction liquid, and heating the second reaction liquid under continuous stirring to form the catalyst.

Abstract: An intraluminal prosthesis (100) and methods thereof for treating at least portal hypertension. The intraluminal prosthesis (100) includes a mixed frame of a main frame (110) and a terminal frame (120), as well as a tubular graft (130) over at least the main frame (110). The main frame (110) includes a plurality of annular members (112). Each annular member (112) includes a plurality of diamond-shaped cells (114). The terminal frame (120) includes woven struts (122). The terminal frame (120) includes a coupled end (124) coupled to at least one of a first-end annular member (112a) or a second-end annular member (112b) respectively at a first end (110a) or a second end (110b) of the main frame (110). The tubular graft (130) extends from the first-end annular member (112a) to the second-end annular member (112b). The intraluminal prosthesis (100) includes an insertion state for inserting the intraluminal prosthesis (100) and an expanded state for use of the intraluminal prosthesis (100) is in use.

Abstract: A novel erythrocyte (red blood cell) membrane coating derived from human red blood cells and the methods of preparation and use thereof are disclosed. The erythrocyte membrane coating may be developed on a piezoelectric sensor coated with poly-L-lysine.

Abstract: An apparatus for generating heterogeneous functional equivalent and method thereof includes: a heterogeneous functional equivalent generator and an element pool connected to the heterogeneous functional equivalent generator, where the element pool includes at least one element. The heterogeneous functional equivalent generator is configured to obtain a generation policy and is further configured to select element sets corresponding to the number from the element pool according to the generation policy. The heterogeneous functional equivalent generator is further configured to generate the number of heterogeneous functional equivalents based on the selected element sets.

Abstract: A use of of ligustrazine nitrone derivatives and a pharmaceutical composition thereof in the preparation of medicine for preventing and treating diabetic complication diseases. The ligustrazine nitrone derivatives can be prepared into various dose forms together with drug carriers.

Abstract: The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (II). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.

Abstract: An apparatus, method, and device for encapsulating heterogeneous functional equivalents are disclosed. The apparatus includes a redundancy controller, an input proxy, and an output proxy. In this application, a plurality of heterogeneous functional equivalents are encapsulated by an input proxy and an output proxy, so that the apparatus can support adaptation, normalization and dis-cooperation to cut a communication link employed by an attacker, such that it is difficult for the attacker to sniff and exploit unknown defects or backdoors, and a success rate of the attacker attacking an information system is reduced.

Abstract: An apparatus for generating heterogeneous functional equivalent and method thereof includes: a heterogeneous functional equivalent generator and an element pool connected to the heterogeneous functional equivalent generator, where the element pool includes at least one element. The heterogeneous functional equivalent generator is configured to obtain a generation policy and is further configured to select element sets corresponding to the number from the element pool according to the generation policy. The heterogeneous functional equivalent generator is further configured to generate the number of heterogeneous functional equivalents based on the selected element sets.

Abstract: A method of synthesizing core-shell nanohybrids is described herein. The method includes providing first nanoparticles and second nanoparticles in a liquid medium at a pH at which the first nanoparticles are neutral and the second nanoparticles are negatively charged, allowing the first nanoparticles to homoaggregate and form a core of at least one of the first nanoparticles, and allowing the second nanoparticles to heteroaggregate with the homoaggregated first nanoparticles to form a shell on the core so as to provide the core-shell nanohybrids. A nanohybrid is additionally described herein, which includes a core including at least one neutral nanoparticle within a shell containing charged nanoparticles, wherein the shell further includes nanogaps configured to allow access of substrates to the core.